NLS Pharmaceutics Highlights Preclinical Results For Parkinson's Disease Treatments
NLS Pharmaceutics Highlights Preclinical Results For Parkinson's Disease Treatments
NLS製藥公司突出帕金森病治療的臨床前結果
Key findings
主要發現
- AEX-23: Its pronounced action as an OX1R agonist combined with positive effects on neurite outgrowth at specific concentrations suggests that it may modulate neuronal health through pathways influencing α-synuclein dynamics, making it a potential therapeutic candidate to improve neuronal connectivity and resilience in PD.
- AEX-19: Its effects at low concentrations on neurite growth coupled with OX1R agonist activity and a moderate increase in CTSD activity suggest potential neuroprotective benefits in PD.
- AEX-24: The increase in CTSD activity and agonist activity on OX1R suggests the potential to enhance α-synuclein degradation, highlighting its promising therapeutic impact on PD.
- AEX-23：其作爲OX1R激動劑的發音與對神經元突起的特定濃度的正面影響相結合，表明它可以通過影響α-突觸核蛋白動力學的途徑調節神經元健康，成爲促進PD神經元連接性和彈性的潛在治療候選藥物。
- AEX-19：其在低濃度下對神經元突起的影響，加上OX1R激動劑活性和CTSD活性的適度增加，表明它可能具有PD領域的潛在神經保護作用。
- AEX-24：CTSD活性的增加和對OX1R的激動作用表明它具有增強α-突觸核蛋白降解的潛力，突顯其對PD的前景治療影響。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。